Page 128 - 中国全科医学2022-21

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·2685·

［33］LEE H C，SHIOU Y L，JHUO S J，et al. The sodium-glucose co- experimental model of pressure overload-induced heart failure［J］.
transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and JACC Basic Transl Sci，2017，2（4）：347-354.
improves ventricular hemodynamics in hypertensive heart failure ［47］VERMA S，GARG A，YAN A T，et al. Effect of empagliflozin
rats［J］. Cardiovasc Diabetol，2019，18（1）：45. DOI： on left ventricular mass and diastolic function in individuals with
10.1186/s12933-019-0849-6. diabetes：an important clue to the EMPA-REG OUTCOME trial?
［34］HEERSPINK H J L，PERCO P，MULDER S，et al. Canagliflozin ［J］. Diabetes Care，2016，39（12）：e212-213.
reduces inflammation and fibrosis biomarkers：a potential ［48］LIM V G，BELL R M，ARJUN S，et al. SGLT2 inhibitor，
mechanism of action for beneficial effects of SGLT2 inhibitors in canagliflozin，attenuates myocardial infarction in the diabetic and
diabetic kidney disease［J］. Diabetologia，2019，62（7）： nondiabetic heart［J］. JACC Basic Transl Sci，2019，4（1）：
1154-1166. DOI：10.1007/s00125-019-4859-4. 15-26. DOI：10.1016/j.jacbts.2018.10.002.
［35］LENG W L，WU M X，PAN H，et al. The SGLT2 inhibitor ［49］RAGGI P，GADIYARAM V，ZHANG C，et al. Statins reduce
dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome epicardial adipose tissue attenuation independent of lipid lowering：
axis in steatohepatitis with diabetes mellitus［J］. Ann Transl a potential pleiotropic effect［J］. J Am Heart Assoc，2019，8（12）：
Med，2019，7（18）：429. DOI：10.21037/atm.2019.09.03. e013104. DOI：10.1161/JAHA.119.013104.
［36］LEE T M，CHANG N C，LIN S Z. Dapagliflozin，a selective
［50］IBORRA-EGEA O，SANTIAGO-VACAS E，YURISTA S R，
SGLT2 inhibitor，attenuated cardiac fibrosis by regulating the et al. Unraveling the molecular mechanism of action of empagliflozin
macrophage polarization via STAT3 signaling in infarcted rat
in heart failure with reduced ejection fraction with or without
hearts［J］. Free Radic Biol Med，2017，104：298-310.
diabetes［J］. JACC Basic Transl Sci，2019，4（7）：831-840.
［37］KANG S A，VERMA S，HASSANABAD A F，et al. Direct effects
DOI：10.1016/j.jacbts.2019.07.010.
of empagliflozin on extracellular matrix remodelling in human cardiac
［51］SATO T，AIZAWA Y，YUASA S，et al. The effect of dapagliflozin
myofibroblasts：novel translational clues to explain EMPA-REG
treatment on epicardial adipose tissue volume［J］. Cardiovasc
OUTCOME results［J］. Can J Cardiol，2020，36（4）：543-
Diabetol，2018，17（1）：6. DOI：10.1186/s12933-017-0658-8.
553. DOI：10.1016/j.cjca.2019.08.033.
［52］ZHOU B，TIAN R. Mitochondrial dysfunction in pathophysiology of
［38］GRUBIC ROTKVIC P，CIGROVSKI BERKOVIC M，BULJ N，
heart failure［J］. J Clin Invest，2018，128（9）：3716-3726.
et al. Minireview：are SGLT2 inhibitors heart savers in diabetes? ［J］.
DOI：10.1172/JCI120849.
Heart Fail Rev，2020，25（6）：899-905.
［53］LI C G，ZHANG J，XUE M，et al. SGLT2 inhibition with
［39］CAI X L，YANG W J，GAO X Y，et al. The association between
empagliflozin attenuates myocardial oxidative stress and fibrosis in
the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes
diabetic mice heart［J］. Cardiovasc Diabetol，2019，18（1）：
patients：a meta-analysis［J］. Obesity （Silver Spring），
15. DOI：10.1186/s12933-019-0816-2.
2018，26（1）：70-80. DOI：10.1002/oby.22066.
［54］UTHMAN L，HOMAYR A，JUNI R P，et al. Empagliflozin and
［40］PEREIRA M J，ERIKSSON J W. Emerging role of SGLT-2
dapagliflozin reduce ROS generation and restore NO bioavailability
inhibitors for the treatment of obesity［J］. Drugs，2019，79（3）：
in tumor necrosis factor α-stimulated human coronary arterial
219-230. DOI：10.1007/s40265-019-1057-0.
endothelial cells［J］. Cell Physiol Biochem，2019，53（5）：
［41］LEE P C，GANGULY S，GOH S Y. Weight loss associated with
865-886. DOI：10.33594/000000178.
sodium-glucose cotransporter-2 inhibition：a review of evidence
［55］PATEL A R，KUVIN J T，PANDIAN N G，et al. Heart failure
and underlying mechanisms［J］. Obes Rev，2018，19（12）：
1630-1641. DOI：10.1111/obr.12755. etiology affects peripheral vascular endothelial function after cardiac
transplantation［J］. J Am Coll Cardiol，2001，37（1）：195-
［42］SATTAR N. Revisiting the links between glycaemia，diabetes and
cardiovascular disease［J］. Diabetologia，2013，56（4）：686- 200. DOI：10.1016/s0735-1097（00）01057-3.
695. DOI：10.1007/s00125-012-2817-5. ［56］LI H L，SHIN S E，SEO M S，et al. The anti-diabetic drug
［43］CANNON C P，PERKOVIC V，AGARWAL R，et al. Evaluating dapagliflozin induces vasodilation via activation of PKG and Kv
the effects of canagliflozin on cardiovascular and renal events in channels［J］. Life Sci，2018，197：46-55. DOI：10.1016/j.
patients with type 2 diabetes mellitus and chronic kidney disease lfs.2018.01.032.
according to baseline HbA1c，including those with HbA1c <7%： ［57］DONNAN J R，GRANDY C A，CHIBRIKOV E，et al.
results from the CREDENCE trial［J］. Circulation，2020，141（5）： Comparative safety of the sodium glucose co-transporter
407-410. DOI：10.1161/CIRCULATIONAHA.119.044359. 2 （SGLT2） inhibitors：a systematic review and meta-
［44］MATTHEWS V B，ELLIOT R H，RUDNICKA C，et al. Role of analysis［J］. BMJ Open，2019，9（1）：e022577. DOI：
the sympathetic nervous system in regulation of the sodium glucose 10.1136/bmjopen-2018-022577.
cotransporter 2［J］. J Hypertens，2017，35（10）：2059-2068. ［58］SHIN S J，CHUNG S，KIM S J，et al. Effect of sodium-glucose
DOI：10.1097/HJH.0000000000001434. co-transporter 2 inhibitor，dapagliflozin，on renal renin-
［45］SANO M. A new class of drugs for heart failure：SGLT2 inhibitors angiotensin system in an animal model of type 2 diabetes［J］.
reduce sympathetic overactivity［J］. J Cardiol，2018，71（5）： PLoS One，2016，11（11）：e0165703. DOI：10.1371/journal.
471-476. DOI：10.1016/j.jjcc.2017.12.004. pone.0165703.
［46］BYRNE N J，PARAJULI N，LEVASSEUR J L，et al. （收稿日期：2022-01-25；修回日期：2022-03-14）
Empagliflozin prevents worsening of cardiac function in an （本文编辑：崔莎）